Skip to content

Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years

Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years in Bandarabbas Children' Hospital

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01396889
Enrollment
100
Registered
2011-07-19
Start date
2010-05-31
Completion date
2011-07-31
Last updated
2011-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper Respiratory Tract Infections

Keywords

Upper Respiratory Tract Infections, Echinacea, viral infections

Brief summary

Acute upper respiratory tract infections are the most commmon infections in children and are associated with complications such as acute otitis media, sinusitis and pneumonia. Echinacea is widely used for treatment of upper respiratoty tract infections. The aim of this study is to evaluate its efficacy as prophilaxis in children 1-5 years old.

Interventions

0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old

DRUGPlacebo

Placebo (0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old) for 3 months

Sponsors

Hormozgan University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
1 Years to 5 Years
Healthy volunteers
Yes

Inclusion criteria

* Childrens 1-5 years old

Exclusion criteria

* Wheezing in previous 3 months requiring bronchodilatator * History of hyperactive reactive airway * using steroid or Echinacea * chronic pulmonary of cardiac disease * Acute respiratory disease within one week before study * Allergic rhinitis * Allergy to Echinacea * avoiding to participate in the study

Design outcomes

Primary

MeasureTime frame
occurrence of upper respiratory tract infection diagnosed by physician according to history and physical examination and laboratory tests if was necessary6 months

Secondary

MeasureTime frame
Drug side effects6 months

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026